{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:23Z","timestamp":1790803283111,"version":"4.1.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:p>\n                    The study aimed to compare the efficacy of intense pulsed light (IPL), 0.05% cyclosporine A (CsA) eye drops, and 3% diquafosol sodium (DQS) eye drops in treating moderate to severe dry eye. A cohort of 180 patients diagnosed with moderate to severe dry eye was enrolled in the Department of Ophthalmology at Quzhou People\u2019s Hospital between October 2, 2023, and October 2, 2024. The patients were randomly assigned to 3 treatment groups: IPL, 0.05% CsA, and 3% DQS, with each group consisting of 60 patients. Ocular surface parameters were assessed at 4-week and 12-week intervals after the initiation of treatment. The primary outcome measure was the change in the corneal fluorescein staining score (CFSS), used to evaluate the therapeutic efficacy of IPL, 0.05% CsA, and 3% DQS eye drops. The secondary outcomes included the Ocular Surface Disease Index (OSDI), Schirmer Tear Test 1 (STT1), tear meniscus height (TMH), and tear breakup time, used to evaluate treatment efficacy. At week 4 post-treatment, the CsA, DQS, and IPL groups demonstrated statistically significant differences in average NBUT, OSDI score, TMH, and STT1 score (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). The IPL group achieved the most favorable outcomes, showing the highest NBUT, TMH, and STT1 scores, along with the lowest OSDI score. Although CFSS values varied among the groups, the differences were not statistically significant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). At week 12 post-treatment, significant differences (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05) were observed among the CsA, DQS, and IPL groups across multiple parameters. The IPL group continued to show superior results, with the highest tear film breakup time, TMH, and STT1 scores, as well as the lowest OSDI and CFSS values. IPL, 0.05% CsA, and 3% DQS eye drops are effective in treating moderate to severe dry eye. Notably, IPL shows significant advantages over CsA and DQS, owing to its noninvasive nature, effective clearance of meibomian gland obstruction, and marked improvement in tear film quality.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046248","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:01:56Z","timestamp":1764972116000},"page":"e46248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of the efficacy of intense pulsed light, 0.05% cyclosporine A eye drops, and 3% diquafosol sodium eye drops in the treatment of moderate to severe dry eye: A prospective cohort study"],"prefix":"10.1097","volume":"104","author":[{"given":"Youlv","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Jiangyin Fifth People\u2019s Hospital, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital, Quzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-6316","authenticated-orcid":false,"given":"Chunyun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital, Quzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1038\/s41598-024-63784-4","article-title":"Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial.","volume":"14","author":"Jin","year":"2024","journal-title":"Sci Rep"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clinthera.2020.12.023","article-title":"Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a multicenter phase II clinical study.","volume":"43","author":"Peng","year":"2021","journal-title":"Clin Ther"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jop.2021.0083","article-title":"Impact of diquafosol ophthalmic solution on tear film and dry eye symptom in type 2 diabetic dry eye: a pilot study.","volume":"38","author":"Zhang","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R4-20260523","doi-asserted-by":"crossref","first-page":"10160","DOI":"10.1021\/acsomega.3c06658","article-title":"Validation of an ion-pair reverse phase high-performance liquid chromatography method for the detection of major components and related substances in diquafosol sodium eye drops.","volume":"9","author":"Wu","year":"2024","journal-title":"ACS Omega"},{"key":"R5-20260523","doi-asserted-by":"crossref","first-page":"1089613","DOI":"10.3389\/fmed.2023.1089613","article-title":"3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study.","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s12325-014-0162-4","article-title":"Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study.","volume":"31","author":"Yamaguchi","year":"2014","journal-title":"Adv Ther"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"3684963","DOI":"10.1155\/2020\/3684963","article-title":"Therapeutic effect of intense pulsed light (IPL) combined with meibomian gland expression (MGX) on meibomian gland dysfunction (MGD).","volume":"2020","author":"Wei","year":"2020","journal-title":"J Ophthalmol"},{"key":"R8-20260523","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.3390\/ijerph17144969","article-title":"Prediction model for dry eye syndrome incidence rate using air pollutants and meteorological factors in South Korea: analysis of sub-region deviations.","volume":"17","author":"Youn","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2021.03.030","article-title":"Systemic conditions associated with severity of dry eye signs and symptoms in the dry eye assessment and management study.","volume":"128","author":"Yu","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"793565","DOI":"10.3389\/fmed.2022.793565","article-title":"Effects of sodium hyaluronate eye drops with or without preservatives on ocular surface bacterial microbiota.","volume":"9","author":"Zhong","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R11-20260523","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/vop.13065","article-title":"Precorneal retention time of ocular lubricants measured with fluorophotometry in healthy dogs.","volume":"26","author":"Bedos","year":"2023","journal-title":"Vet Ophthalmol"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00417-020-05043-6","article-title":"Topical administration of ambroxol eye drops augments tear secretion in rabbits.","volume":"259","author":"Yu","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-20260523","first-page":"269","article-title":"Oral pilocarpine for the treatment of dry eye in patients with Sj\u00f6gren\u2019s syndrome.","volume":"85","author":"Felberg","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13643-022-01979-4","article-title":"Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a systematic review.","volume":"11","author":"Serrano-Robles","year":"2022","journal-title":"Syst Rev"},{"key":"R15-20260523","first-page":"615","article-title":"Clinical study on the effect of preloaded punctal plug in the treatment of aqueous-deficient dry eye.","volume":"93","author":"Luo","year":"2022","journal-title":"Ann Ital Chir"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jcjo.2019.04.004","article-title":"Levator\u2013Muller\u2019s recession using labial mucosa as a spacer in severe eyelid retraction.","volume":"54","author":"Pushker","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtos.2022.07.013","article-title":"Salivary gland transplantation for dry eye disease: indications, techniques, and outcomes.","volume":"26","author":"Singh","year":"2022","journal-title":"Ocul Surf"},{"key":"R18-20260523","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.12998\/wjcc.v12.i25.5665","article-title":"Analyze interleukin-1\u03b2, interleukin-6, and tumor necrosis factor-\u03b1 levels in dry eye and the therapeutic effect of cyclosporine A.","volume":"12","author":"Wu","year":"2024","journal-title":"World J Clin Cases"},{"key":"R19-20260523","doi-asserted-by":"crossref","first-page":"e34923","DOI":"10.1097\/MD.0000000000034923","article-title":"A randomized controlled trial involving college student: comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the treatment of dry eye.","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R20-20260523","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s10792-022-02584-z","article-title":"Analysis of risk factors for dry eye disease and effect of diquafosol sodium ophthalmic solution on the tear film after vitrectomy in patients with type 2 diabetes mellitus: a preliminary study.","volume":"43","author":"Du","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R21-20260523","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICL.0000000000001040","article-title":"Effect of 3% diquafosol sodium on dry eye after femtosecond laser-assisted in situ keratomileusis and small incision lenticule extraction surgery in high-myopic eyes.","volume":"49","author":"Gao","year":"2023","journal-title":"Eye Contact Lens"},{"key":"R22-20260523","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4103\/IJO.IJO_268_23","article-title":"Safety and efficacy of topical diquafosol for the treatment of dry eye disease: an updated meta-analysis of randomized controlled trials.","volume":"71","author":"Liu","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R23-20260523","first-page":"CD010051","article-title":"Topical cyclosporine A therapy for dry eye syndrome.","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R24-20260523","doi-asserted-by":"crossref","first-page":"19279","DOI":"10.1038\/s41598-023-46671-2","article-title":"Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sj\u00f6gren\u2019s syndrome: a randomized trial.","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"R25-20260523","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options.","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R26-20260523","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/tjo.TJO-D-22-00140","article-title":"Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.","volume":"13","author":"Chan","year":"2023","journal-title":"Taiwan J Ophthalmol"},{"key":"R27-20260523","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial.","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R28-20260523","doi-asserted-by":"crossref","first-page":"e0293472","DOI":"10.1371\/journal.pone.0293472","article-title":"Relationship between ocular surface temperature and 0.1% cyclosporine a in dry eye syndrome with meibomian gland dysfunction.","volume":"18","author":"Lee","year":"2023","journal-title":"PLoS One"},{"key":"R29-20260523","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.18240\/ijo.2022.12.05","article-title":"Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction.","volume":"15","author":"Jo","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R30-20260523","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R31-20260523","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00417-022-05682-x","article-title":"Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients.","volume":"260","author":"Shin","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R32-20260523","doi-asserted-by":"crossref","first-page":"e2022","DOI":"10.5935\/0004-2749.2022-0192","article-title":"20% Autologous serum vs. 0.05% cyclosporine and preservative-free artificial tears in the treatment of Sj\u00f6gren related dry eye.","volume":"87","author":"Berhuni","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"R33-20260523","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2015.12.002","article-title":"Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial.","volume":"163","author":"Park","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R34-20260523","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.18240\/ijo.2023.12.02","article-title":"Effects of diquafosol sodium in povidone iodine-induced dry eye model.","volume":"16","author":"Zhang","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"R35-20260523","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neures.2023.01.003","article-title":"Tear secretion by Diquafosol suppresses the excitability of trigeminal brainstem nuclear complex neurons by reducing excessive P2Y2 expression in the trigeminal ganglion in dry eye rats.","volume":"191","author":"Katagiri","year":"2023","journal-title":"Neurosci Res"},{"key":"R36-20260523","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/15569527.2021.1973022","article-title":"Effects of eye drops containing a mixture of 3% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye.","volume":"40","author":"Li","year":"2021","journal-title":"Cutan Ocul Toxicol"},{"key":"R37-20260523","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/jcm11133719","article-title":"Lipid, aqueous and mucin tear film layer stability and permanence within 0.15% liposome crosslinked hyaluronic acid versus 0.15% non-crosslinked hyaluronic acid measured with a novel non-invasive ocular surface analyzer.","volume":"11","author":"S\u00e1nchez-Gonz\u00e1lez","year":"2022","journal-title":"J Clin Med"},{"key":"R38-20260523","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/jop.2023.0098","article-title":"Effects of diquafosol sodium ophthalmic solution on tear film matrix metallopeptidase-9 and corneal nerve density in patients with type 2 diabetic dry eye.","volume":"40","author":"Qin","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"R39-20260523","doi-asserted-by":"crossref","first-page":"973962","DOI":"10.3389\/fendo.2022.973962","article-title":"Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye.","volume":"13","author":"Yu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R40-20260523","doi-asserted-by":"crossref","first-page":"e33852","DOI":"10.1016\/j.heliyon.2024.e33852","article-title":"The photothermal effect of intense pulsed light and LipiFlow in eyelid related ocular surface diseases: meibomian gland dysfunction, Demodex and blepharitis.","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"R41-20260523","first-page":"178","article-title":"Safety and efficacy of an augmented intense pulse light protocol for dry eye syndrome and blepharitis.","volume":"39","author":"Zhang-Nunes","year":"2021","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"R42-20260523","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jfo.2022.03.015","article-title":"Optimized combined low level light therapy and intense pulsed light therapy for the treatment of dry eye syndrome caused by meibomian glands dysfunction.","volume":"45","author":"El Shami","year":"2022","journal-title":"J Fr Ophtalmol"},{"key":"R43-20260523","doi-asserted-by":"crossref","first-page":"2023246","DOI":"10.1155\/2021\/2023246","article-title":"Combined low-level light therapy and intense pulsed light therapy for the treatment of dry eye in patients with Sj\u00f6gren\u2019s syndrome.","volume":"2021","author":"Di Marino","year":"2021","journal-title":"J Ophthalmol"},{"key":"R44-20260523","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/ICL.0000000000000704","article-title":"A retrospective study of treatment outcomes and prognostic factors of intense pulsed light therapy combined with meibomian gland expression in patients with meibomian gland dysfunction.","volume":"47","author":"Tang","year":"2021","journal-title":"Eye Contact Lens"},{"key":"R45-20260523","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3341\/kjo.2022.0068","article-title":"Different number of sessions of intense pulsed light and meibomian gland expression combination therapy for meibomian gland dysfunction[J\/OL].","volume":"36","author":"Lee","year":"2022","journal-title":"Korean J Ophthalmol"},{"key":"R46-20260523","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10792-022-02389-0","article-title":"Intense pulsed light treatment of the upper and lower eyelids in patients with moderate-to-severe meibomian gland dysfunction.","volume":"43","author":"Chung","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R47-20260523","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/02713683.2022.2147955","article-title":"The approach of intense pulsed light treatment in patients with different severities of meibomian gland dysfunction.","volume":"48","author":"Yin","year":"2023","journal-title":"Curr Eye Res"},{"key":"R48-20260523","first-page":"472","article-title":"Real-time video microscopy of in vitro Demodex death by intense pulsed light.","volume":"38","author":"Fishman","year":"2020","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"R49-20260523","doi-asserted-by":"crossref","first-page":"22180","DOI":"10.1038\/s41598-024-73215-z","article-title":"Evaluating the role of Demodex infestation and meibomian gland dysfunction in recurrent corneal erosion syndrome.","volume":"14","author":"Niu","year":"2024","journal-title":"Sci Rep"},{"key":"R50-20260523","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/08164622.2021.1976595","article-title":"Efficacy of five-flash intense pulsed light therapy technique in patients with meibomian gland dysfunction.","volume":"105","author":"Zarei-Ghanavati","year":"2022","journal-title":"Clin Exp Optom"},{"key":"R51-20260523","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.4103\/IJO.IJO_2834_22","article-title":"A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye.","volume":"71","author":"D\u2019Souza","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R52-20260523","doi-asserted-by":"crossref","first-page":"e078727","DOI":"10.1136\/bmjopen-2023-078727","article-title":"Comparison of non-pharmaceutical treatments for evaporative dry eye: a randomised controlled study protocol.","volume":"14","author":"Chen","year":"2024","journal-title":"BMJ Open"},{"key":"R53-20260523","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10103-022-03690-1","article-title":"Intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD)-related dry eye disease (DED): a systematic review and meta-analysis.","volume":"38","author":"Lei","year":"2022","journal-title":"Lasers Med Sci"},{"key":"R54-20260523","doi-asserted-by":"crossref","first-page":"e0270268","DOI":"10.1371\/journal.pone.0270268","article-title":"Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: a randomized controlled study.","volume":"17","author":"Toyos","year":"2022","journal-title":"PLoS One"},{"key":"R55-20260523","doi-asserted-by":"crossref","first-page":"e32292","DOI":"10.1097\/MD.0000000000032292","article-title":"Efficacy of intense pulsed light and meibomian gland expression treatments in meibomian gland dysfunction: a meta-analysis of randomized controlled trials.","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltim)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:02:58Z","timestamp":1779530578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":55,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046248","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2024-12-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}